Substance / Medication

Troglitazone

Overview

Active Ingredient
troglitazone
RxNorm CUI
72610

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

903 trials linked to this intervention

903
Total Trials
103
Recruiting
282
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
Lord J M, Flight I H K, Norman R J · Cochrane Database Syst Rev · 2003
PMID: 12917943Meta-Analysis
Sequence variation in PPARG may underlie differential response to troglitazone.
Wolford Johanna K, Yeatts Kimberly A, Dhanjal Sharanjeet K et al. · Diabetes · 2005
PMID: 16249460RCTFull text (PMC)
The metabolic effects of troglitazone in patients with diabetes and end-stage renal disease.
Mohideen Pharis, Bornemann Michael, Sugihara Jared et al. · Endocrine · 2005
PMID: 16388091RCT
Troglitazone metabolism and transporter effects in chimeric mice: a comparison between chimeric humanized and chimeric murinized FRG mice.
Samuelsson Kristin, Pickup Kathryn, Sarda Sunil et al. · Xenobiotica · 2014
PMID: 24417752Observational
Comparison of the anti-inflammatory and therapeutic actions of PPAR-gamma agonists rosiglitazone and troglitazone in experimental colitis.
Celinski K, Dworzanski T, Fornal R et al. · J Physiol Pharmacol · 2012
PMID: 23388479Observational
New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
Colin Christelle, Salamone Stéphane, Grillier-Vuissoz Isabelle et al. · Breast Cancer Res Treat · 2010
PMID: 20054646Observational
Multiple mechanisms underlying troglitazone-induced mitochondrial permeability transition.
Okuda Takuya, Norioka Misaki, Shitara Yoshihisa et al. · Toxicol Appl Pharmacol · 2010
PMID: 20709092Observational
Prediction of recrystallization behavior of troglitazone/polyvinylpyrrolidone solid dispersion by solid-state NMR.
Ito Atsutoshi, Watanabe Tomoyuki, Yada Shuichi et al. · Int J Pharm · 2010
PMID: 19732816Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Troglitazone (substance)
SNOMED CT
386967007
UMLS CUI
C0245514
RxNorm CUI
72610

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

1
Conditions
4
Biomarkers
3
Specialists
0
Symptoms
903
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Troglitazone — Conditions, Biomarkers & Specialists | Healos | Healos